Phaseline

Companies › NGGT

NGGT: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NGGT002
Adeno-associated viral vector with human phenylalanine hydroxylase gene
PAHPhase 1PhenylketonuriasDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06332807NGGT002Phase 1PhenylketonuriasMetabolic and endocrineDec 2030

Targets

PAH (1)

Companies with the same targets

BioMarin Pharmaceutical PTC Therapeutics Chongqing Peg-Bio Biopharm Agios Pharmaceuticals NGGT (Suzhou) Biotechnology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.